PLK
PLK (Polo-like Kinase) inhibitors target PLKs, a family of serine/threonine kinases that are essential for various stages of cell division, including mitotic entry, spindle assembly, and cytokinesis. PLKs are critical for the proper execution of the cell cycle, and their dysregulation is often associated with cancer. Inhibiting PLKs can induce cell cycle arrest and apoptosis in cancer cells, making these inhibitors important tools in cancer research and therapy. At CymitQuimica, we offer a range of high-quality PLK inhibitors to support your research in mitosis, cell cycle control, and oncology.
Found 29 products for "PLK".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
PROTAC PLK1 Degrader-3
CAS:PROTACPLK1 Degrader-3 (Compound DD-1) is a PLK1 PROTAC degrader that operates via the N-deglycosylation pathway, with a dissociation constant (Kd) of 2.2 μM. Its cell permeability is limited, requiring higher concentrations to achieve a notable degradation effect. PROTACPLK1 Degrader-3 is applicable in research on non-small cell lung cancer.Formula:C102H196N57O23PMolecular weight:2620.04PLK1-IN-12
PLK1-IN-12 is a highly selective, orally active PLK1 inhibitor with an IC50 of 20 nM. It demonstrates greater selectivity for PLK1 over PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer efficacy across a wide range of cell lines and is applicable to anti-leukemia research.Color and Shape:Odour SolidRP-1664
CAS:RP-1664,PLK4 inhibitor (IC50=3 nM). Disrupts centriole biogenesis. Antitumor activity in breast cancer, neuroblastoma.Formula:C23H24F2N8O2SPurity:99.04%Color and Shape:SolidMolecular weight:514.55PLK1-IN-14
PLK1-IN-14 (Compound Hit-4) is a selective PLK1 inhibitor with an IC50 of 22.61 pM for PLK1, and an IC50 of 0.09 nM for inhibiting the proliferation of DU-145 prostate cancer cells. It is applicable in prostate cancer research.Color and Shape:Odour SolidSP27
CAS:SP27, a selective PROTAC, degrades PLK4 with a DC50 of 19.5 nM and may be utilized in breast cancer research [1].Formula:C40H40F2N12O5Purity:98%Color and Shape:SolidMolecular weight:806.82PLK1 Protein, Human, Recombinant (His)
PLK1 Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with His tag.Purity:96.8%Color and Shape:Lyophilized PowderMolecular weight:70.5 kDa (predicted); 66 kDa (reducing conditions)PLK1 Protein, Mouse, Recombinant (His)
PLK1 Protein, Mouse, Recombinant (His) is expressed in Baculovirus insect cells with His tag.Color and Shape:Lyophilized PowderMolecular weight:70.6 kDa (predicted); 65 kDa (reducing conditions)Poloxime
CAS:Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.Formula:C10H13NO2Purity:98%Color and Shape:SolidMolecular weight:179.22GSK461364
CAS:GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.Formula:C27H28F3N5O2SPurity:99% - 99.93%Color and Shape:SolidMolecular weight:543.604Poloxin
CAS:Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).Formula:C18H19NO3Purity:98.17%Color and Shape:SolidMolecular weight:297.3484SBE13
CAS:SBE13 is a highly selective PLK1 inhibitor (IC₅₀=200 pM), a type II inhibitor with anti-tumor activity.Formula:C24H27ClN2O4Purity:99.59%Color and Shape:SolidMolecular weight:442.9355-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE
CAS:5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE targets PLK1.Formula:C8H13N3SPurity:99.03%Color and Shape:SolidMolecular weight:183.274HMN-214
CAS:HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.Formula:C22H20N2O5SPurity:98% - >99.99%Color and Shape:SolidMolecular weight:424.47TAK-960
CAS:TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.Formula:C27H34F3N7O3Purity:97.06%Color and Shape:White SolidMolecular weight:561.5992Ro3280
CAS:Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).Formula:C27H35F2N7O3Purity:97.76% - >99.99%Color and Shape:SolidMolecular weight:543.6087MLN0905
CAS:MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).Formula:C24H25F3N6SPurity:98% - 99.92%Color and Shape:Yellow SolidMolecular weight:486.556(1E)-CFI-400437 dihydrochloride
CAS:(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor.Formula:C29H30Cl2N6O2Purity:97.08%Color and Shape:Orange SolidMolecular weight:565.493HMN-176
CAS:HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).Formula:C20H18N2O4SPurity:98.92% - 98.99%Color and Shape:SolidMolecular weight:382.433PLK1-IN-9
CAS:PLK1-IN-9 (Compound M2), a polo-like kinase 1 (PLK1) inhibitor, targets the PLK proteins modified with peptides 1010pT, cdc25c, and PBIP, exhibiting IC50 values of 1.6, 0.8, and 1.4 μM, respectively. This compound effectively inhibits the proliferation of various cancer cell lines including HeLa, HL60, SNU387/499, and HepG2, demonstrating cytotoxic effects and inducing apoptosis. Additionally, PLK1-IN-9 has been shown to suppress tumor growth in a HepG2 xenograft mouse model.Formula:C12H7F3N4O2Molecular weight:296.2048Centrinone-B
CAS:Centrinone-B (LCR-323) is a Plk4 inhibitor with potential anticancer activity for the study of triple-negative breast cancer.Formula:C27H27F2N7O5S2Purity:98.71%Color and Shape:SolidMolecular weight:631.67
![5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE](https://static.cymitquimica.com/products/TM/thumb-webp/T8912.webp)
